⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
REGN News
Regeneron Pharmaceuticals Inc
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
accessnewswire.com
REGN
Pomerantz LLP Issues Alert Regarding Shareholder Class Action Against Regeneron Pharmaceuticals, Inc. – REGN
accessnewswire.com
REGN
Did You Lose Money on Regeneron Pharmaceuticals, Inc. (REGN)? Levi & Korsinsky Urges Investors to Act Before September 14, 2026
accessnewswire.com
REGN
Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REGN
prnewswire.com
REGN
Contact Levi & Korsinsky by September 14, 2026 to Join Class Action Against Regeneron Pharmaceuticals, Inc. (REGN)
accessnewswire.com
REGN
REGN Shareholder Alert: September 14, 2026 Lead Plaintiff Deadline in Regeneron Pharmaceuticals Securities Class Action - Contact SueWallSt
prnewswire.com
REGN
United States Pharmaceutical Contract Manufacturing Organization Report (2026-2031) - Rising Pharmaceutical Manufacturing Outsourcing Drives Market Growth
globenewswire.com
NVO
LLY
TMO
PFE
BIIB
AMGN
GILD
BMY
REGN
ABBV
EXAS
CRSP
EDIT
EMR
Rare Disease Treatment (2026-2031) - Expanding Orphan Drug Development Drives Market Growth
globenewswire.com
JNJ
AMGN
PFE
BMY
VRTX
BMRN
ULTA
REGN
SRPT
HRZN
PTC
Biologics CDMO (2026-2031) - Growing Biologics Pipeline Drives Demand for Outsourced Development and Manufacturing
globenewswire.com
NVO
TMO
ABBV
CAT
EXEL
REGN
BMY
PFE
MRK
AMGN
GILD
BIIB
ISRG
CRSP
EDIT
NTLA
VRTX
AZN
SNY
LLY
JNJ
XOM
CVX
Multispecific Antibodies Market Report 2026: Forecast to Reach $60 Billion by 2031, Driven by Expanding Clinical Pipeline and Proprietary Technologies
globenewswire.com
AMGN
JNJ
PFE
REGN
MRK
ABBV
BMY
GILD
AZN
XNCR
GEN
ABL